


# Journal Pre-proof

Safety and efficacy profile of anti-IL17 treatments in hidradenitis suppurativa: systematic review and meta-analysis of randomized placebo-controlled trials

O. Al-wattar-Ceballos L. Martínez-Montalvo M. Carmona-Rodríguez



PII: S0001-7310(25)00362-X

DOI: <https://doi.org/doi:10.1016/j.ad.2024.12.027>

Reference: AD 4379

To appear in: *Actas dermosifiliograficas*

Received Date: 10 September 2024

Accepted Date: 7 December 2024

Please cite this article as: Al-wattar-Ceballos O, Martínez-Montalvo L, Carmona-Rodríguez M, Safety and efficacy profile of anti-IL17 treatments in hidradenitis suppurativa: systematic review and meta-analysis of randomized placebo-controlled trials, *Actas dermosifiliograficas* (2025), doi: <https://doi.org/10.1016/j.ad.2024.12.027>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2025 AEDV. Published by Elsevier España, S.L.U.

**Sección: artículo original**

**TITLE:** Safety and efficacy profile of anti-IL17 treatments in hidradenitis suppurativa: systematic review and meta-analysis of randomized placebo-controlled trials

**TÍTULO:** Eficacia y seguridad de los tratamientos anti-IL17 en la hidradenitis supurativa: revisión sistemática y meta-análisis de ensayos aleatorizados controlados con placebo

**Authors:** O. Al-wattar-Ceballos<sup>\*1</sup>, L. Martínez-Montalvo<sup>1</sup>, and M. Carmona-Rodríguez<sup>1</sup>

**Affiliation:** <sup>1</sup>Dermatology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain.

**Corresponding author:** \*Omar Al-wattar-Ceballos;

E-mail address: oalwattar@sescam.jccm.es

**ABSTRACT**

**Background and objective:** Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease that is difficult to manage, requiring the use of biologic drugs such as anti-TNF $\alpha$  and anti-interleukin 17 (anti-IL17). The aim of our review is to evaluate the safety and efficacy profile of anti-IL17 drugs in patients with HS.

**Materials and methods:** We conducted a systematic review with subsequent meta-analysis following the population, intervention, comparison, outcome and type of study (PICOS) method. We included only randomized clinical trials with placebo (S) that included individuals with HS > 18 years old (P), and who had been on placebo (C) OR, an anti-IL17 biologic drug (I) to measure safety and efficacy outcomes (O). Search was conducted across multiple databases: PubMed, Scopus, and the Cochrane Central Register of Controlled Trials. The risk of bias of each study, publication bias, sensitivity analysis, and certainty of evidence were determined.

**Results:** A total of 320 bibliographic references were obtained, 4 of which met the inclusion criteria. Compared to placebo, the meta-analysis showed a significantly higher percentage of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) OR, of 1.96 [1.79-2.15], a greater decrease in DLQI, MD -1.92 [-2.68,-1.16] and an increase in adverse effects; OR, 1.21 [1.09, 1.34], particularly due to Candida infections; OR, 5.61 [2.66-11.83].

**Conclusions:** Treatment with anti-IL17 biologic drugs is effective in patients with moderate-to-severe HS. Although these drugs are safe, they should be monitored due to the risk of infections, mainly candidiasis.

**KEYWORDS:** Suppurative Hidradenitis; Interleukin 17; Adults; Treatment; Meta-Analysis

**RESUMEN**

**Antecedentes y objetivo:** La hidradenitis supurativa (HS) es una enfermedad inflamatoria crónica de la piel que puede requerir el uso de fármacos biológicos como los anti-TNF $\alpha$  y los anti-interleucina 17 (anti-IL17). El objetivo de nuestra revisión es evaluar la eficacia y seguridad de los fármacos anti-IL17 en pacientes con HS.

**Material y métodos:** Se realizó una revisión sistemática con posterior, metaanálisis siguiendo el método de población, intervención, comparación, resultado y tipo de estudio (PICOS). Se incluyeron únicamente ensayos clínicos aleatorizados con placebo (S) que incluyeran individuos con HS  $\geq$  a 18 años de edad (P), que hubieran recibido placebo (C) o un fármaco biológico anti-IL17 (I) para medir los resultados de eficacia y seguridad (O). La búsqueda se realizó en: PubMed, Scopus y el Registro Cochrane Central de Ensayos Controlados (Cochrane Central

Register of Controlled Trials). Se determinó el riesgo de sesgo de cada estudio, el sesgo de publicación, el análisis de sensibilidad y la certeza de la evidencia.

**Resultados:** Se obtuvo un total de 320 referencias bibliográficas, cuatro cumplieron los criterios de inclusión. El metaanálisis mostró de forma significativa un mayor, porcentaje de pacientes que alcanzaban el Hidradenitis Suppurativa Clinical Response (HiSCR) OR, 1,96 [1,79-2,15], una mayor, disminución del DLQI, Diferencia media de -1,92 [-2,68,-1,16] y un aumento de los efectos adversos (OR, 1,21 [1,09, 1,34]), especialmente por, infecciones por, Cándida, OR, 5,61 [2,66-11,83].

**Conclusiones:** El tratamiento con fármacos biológicos anti-IL17 es eficaz en el manejo de pacientes con HS moderada-grave. Aunque estos fármacos son seguros, deben ser monitorizados debido al riesgo de infecciones, principalmente candidiasis.

**PALABRAS CLAVE:** Hidradenitis Suppurativa; Interleucina-17; Adultos, Tratamiento; Metaanálisis

## INTRODUCTION

Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the pilosebaceous-apocrine unit. It occurs in outbreaks of erythematous nodules, abscesses and tunnels mainly in the axillary, submammary, inguinal and anogenital areas. This disease is accompanied by pain and a very intense affectation of the quality of life<sup>1-2</sup>.

Although the exact prevalence is still unknown, it is estimated to be around 0.4% worldwide<sup>2</sup>, with an annual incidence rate of 6 cases per 100,000 inhabitants<sup>3</sup>. It is considered an under-diagnosed entity<sup>4</sup>.

Among therapeutic tools<sup>5</sup> are topical and intralesional therapies<sup>6</sup>, systemic antibiotic treatments, surgical procedures, and more recently, biologic treatments have been included, being adalimumab the first biologic drug with an indication for the treatment of HS, having proven superior, to placebo in moderate-to-severe HS<sup>5,7</sup>.

Although the pathophysiology of HS is not fully elucidated, an interaction between innate immunity, via the inflammasome pathway, and adaptive immunity via the Th1 and Th17 pathways, with increased interleukin-17 (IL-17) and TNF- $\alpha$ , is assumed. Interestingly, higher levels of IL-17 have been found in the serum of patients with more severe HS<sup>8</sup>.

A previous systematic review from 2022 on anti-interleukin 17 (anti-IL17) treatments in the management of HS supported its efficacy profile and use as a therapeutic alternative in patients refractory to other treatments<sup>9</sup>.

Secukinumab and bimekizumab are 2 marketed anti-IL17 biologic drugs that currently have randomized clinical trials (RCTs) in HS demonstrating its efficacy profile<sup>10-12</sup>. However meta-analyses including the most recent clinical trials, particularly those of bimekizumab<sup>12</sup>, are lacking.

Therefore, due to the impact this disease has on the patients' quality of life and need for, effective therapeutic tools, this systematic review and meta-analysis is justified to measure the safety and efficacy profile of treatment with anti-IL17 in HS.

## METHODS

### Eligibility criteria

This meta-analysis was registered with PROSPERO (CRD42024538548). This study adhered to PRISMA guidelines<sup>13</sup> (Supplementary file 1).

The research question was formulated according to the PICOS strategy:

- P (Population): Adult patients aged 18 years and older who had been diagnosed with HS.
- I (Intervention): Anti-interleukin 17 treatments.
- C (Comparator): Placebo therapy.
- O (Outcome): The primary outcome of interest was the safety and efficacy profile of anti-IL17 treatments in patients with HS. This included the metrics of Hidradenitis Suppurativa Clinical Response (HiSCR), including HiSCR75 and HiSCR90, Dermatology Life Quality Index (DLQI) as a Patient-Reported Outcome Measure (PROM), the incidence rate of patients with adverse events, serious adverse events, headache, infections and infestations of any organs, candida infections, inflammatory bowel disease and treatment withdrawal.
- S (Study design): Only randomized placebo-controlled clinical trials were eligible for inclusion.

Exclusion criteria were applied to ensure the quality and comparability of the included studies. Observational studies, both case-control and cohort studies, were excluded. Systematic reviews and literature reviews were excluded too. Duplicates: Multiple reports on the same study were excluded to avoid duplication of data.

### Information sources

An extensive literature review was conducted using multiple **databases**, including PubMed, Scopus, and the Cochrane Central Register of Controlled Trials from inception until June 9<sup>th</sup>, 2024 (Fig. 1). A systematic and rigorous methodology was used to search for relevant studies, without establishing a specific **time** OR, **language** limit. A thorough review of the **bibliographic references** of the selected studies in the first phase of the search was conducted to identify any additional studies that might have been omitted from the initial search.

### Search methods for study identification

We used the following **search terms** to search all trial registers and databases: (hidradenitis suppurativa OR, acne inversa) AND (IL-17 OR, IL17A OR, bimekizumab OR, secukinumab) (*Supplementary File 2*). **Two reviewers** (AO/ML) independently agreed on the selection of eligible studies and reached a **consensus** on the studies that should be included.

### Data extraction and data items

Two authors (AO/ML) independently reviewed the data extracted from the studies. If consensus was not reached, a third author, (CM) was consulted to complete the data-extraction form. The following data were collected: baseline characteristics of the articles, author, and year of publication, study type, clinical trial identifier, study design, primary endpoint in weeks, severity, sample size, age, number of women, outcomes and conflicts of interest related to the pharmaceutical industry.

In RCTs involving more than one arm with an anti-IL17, each of them was analyzed separately.

One of the compared variables was the HiSCR, at 2, 4, 12 and 16 weeks. HiSCR is an endpoint regardless of lesion size, pain or impact on quality of life. It is defined as, at least, a 50%

reduction in the total abscess and inflammatory nodules count with no increase in abscess count or draining tunnel count relative to baseline<sup>14</sup>. Efficacy data were extracted at weeks 2 and 4 to assess speed, and efficacy data were extracted at weeks 12 and 16 since these were the endpoints of the studies. HiSCR75 and HiSCR90 values were also extracted if reported. As PROM, the mean change and its standard deviation of the DLQI was extracted if reported by the studies. For safety outcomes, comparisons could be drawn using the incidence rate of patients with adverse events, serious adverse events, headache, infections and infestations of any organs, candida infections, inflammatory bowel disease and treatment withdrawal.

### **Risk of bias**

The methodological quality and risk of bias (RoB) of the included RCTs were independently evaluated by 2 reviewers using the Cochrane Collaboration's risk of bias tool (Review Manager software). This tool systematically assesses 6 key domains related to bias: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting. For each domain, explicit prespecified criteria were used to assign ratings of low, high, or unclear RoB. The results of the RoB are shown in **Figure 2** and the justification for each criterion can be consulted in the **Supplementary File 3**.

### **Assessment of results**

Mean differences (MD) and 95% confidence intervals (CI) were estimated for continuous variables measured on the same scale. Odds ratios (OR) were calculated for the dichotomous variables. Heterogeneity was assessed using the  $I^2$  statistic, with values < 25%, 25-50%, and > 50% indicating low, moderate, and high heterogeneity, respectively. A fixed-effects model was used when no significant heterogeneity was observed. Incomplete data reporting across studies was addressed following methodological guidance from the Cochrane Handbook<sup>15</sup>. Review Manager 5.4 statistical software was used for all analyses. Web-PlotDigitizer version 4.7 was used to obtain information from the figures in the articles. A level of threshold of statistical significance was considered if  $p < 0.05$ .

### **Publication bias**

Funnel plot analysis was conducted using Review Manager 5.4 software to assess potential reporting bias. Funnel plot asymmetry can suggest a publication bias arising from the non-publication of smaller studies with null or, inconclusive findings.

### **Additional analyses**

Subgroup analyses were performed based on follow-up time in case of HiSCR, specifically at 2, 4, 12 and 16 weeks, and based on different adverse event variables in the safety outcomes.

Due to interest in real-world clinical practice, the safety and efficacy data for bimekizumab and secukinumab have been analyzed separately.

Sensitivity analysis removing studies of non-commercialized drugs for each outcome and reanalyzing data was conducted using Review Manager 5.4 to assess the robustness of the results and evaluate the impact of excluding individual studies on the overall interpretations.

### **Grading of certainty of evidence**

The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) approach, utilizing GRADEpro, was used to assess the certainty of the outcomes<sup>16</sup>. GRADE evaluates the quality of evidence based on factors such as study design, RoB, inconsistency,

indirectness, imprecision, and publication bias. Data used were those entered in Review Manager 5.4.

## RESULTS

### Study selection

The initial search yielded a total of 320 articles from databases. After removing duplicates and reviews based on titles and abstracts, a total of 256 articles were excluded, resulting in 64 articles. After reviewing the full texts, 60 studies were excluded for not meeting the inclusion criteria. Finally, 4 studies were included in the systematic review and meta-analysis<sup>10-12, 17</sup> (**fig. 1**).

### Study characteristics

**Table 1** illustrates the main characteristics of the included studies. Two articles reported on 2 different clinical trials each. Four articles with 2,231 patients were included (1,668 from the anti-IL17 group and 563 from the placebo group). All studies included were randomized placebo-controlled clinical trials. The number of women was generally higher compared with men in the studies. The patients' mean age in the studies is shown in table 1. The severity of HS in all studies was moderate-to-severe. Only data from the first period of the clinical trials were exported to avoid overall bias and period effect.

### Risk of bias

The RoB of the first period of each clinical trial was analyzed. The RoB results are shown in **Figure 2**. In clinical trial NCT02421172, random sequence generation and allocation concealment were scored with "unclear risk of bias" since they were not detailed. It was marked as "high risk of bias" in blinding of outcome assessment because it was not reported. For the rest of the studies a low risk of bias was considered.

### Outcomes

Treatment with anti-IL17 in HS showed a higher percentage of patients achieving HiSCR significantly vs placebo (OR, 1.96 [1.79-2.15]). Analyzed by weeks, a higher percentage of patients achieved HiSCR from week 2 (OR, 1.90 [1.52-2.38]) to week 4 (OR, 2.15 [1.79-2.59]), week 12 (OR, 2.04 [1.72-2.42]) and week 16 (OR, 1.78 [1.51-2.11]) (**fig. 3**). Regarding the HiSCR75 variable, treatment with anti-IL17 showed a significantly higher percentage (OR, 2.46 [1.77,3.43]) of patients achieving this response vs placebo, but not so much for the HiSCR90 variable (OR, 1.43 [0.81,2.51]) (**fig. 4**). Regarding PROM, treatment with anti-IL17 showed a significantly greater decrease in DLQI (MD -1.92 [-2.68-1.16]) (**fig. 5**).

Treatment with anti-IL17 showed a significant increase in adverse effects vs placebo; OR, 1.21 [1.09, 1.34]. No differences were found regarding the number of patients experiencing adverse events; OR, 1.02 [0.86-1.20]. There were no significant differences in serious adverse events (OR, 1.14 [0.68-1.92]), headache (OR, 1.17 [0.87-1.56]), development of inflammatory bowel disease (OR, 2.06 [0.50-8.48]) or in the rate of adverse event-related treatment withdrawal (OR, 1.90 [1.00-3.59]). Significant differences were found regarding a higher rate of infections and infestations of any organ (OR, 1.23 [1.03-1.46]) and Candida infections (OR, 5.61 [2.66-11.83]) with the use of anti-IL17 vs placebo (**Table 2 and Supplementary file 4**).

A separate analysis of the safety and efficacy results for bimekizumab and secukinumab is shown in **Table 3 and Supplementary data 5**. In terms of efficacy, the results of bimekizumab with respect to obtaining HiSCR show an OR > 2 two weeks into therapy, with a total OR of 2.30 [1.98, 2.69], with respect to the total OR of secukinumab (1.83 [1.63, 2.06]), whose results



are lower on the subanalyses conducted on weeks 2, 4, 12 and 16. However, regarding safety variables, secukinumab shows no difference with respect to placebo regarding the rate of adverse effects (OR, 1.04 [0.91, 1.19]), including candidiasis (2.22 [0.84, 5.87]) vs an increase in adverse effects vs placebo with the use of bimekizumab (OR, 1.55 [1.30, 1.85]), with significant differences being due to a greater increase in infections and infestations of any organ (OR, 1.96 [1.44-2.67]), mainly candidiasis (OR, 11.64 [3.25-41.68]), and treatment withdrawal due to adverse effects (OR, 3.35 [1.09-10.27]).

### **Additional analyses**

#### ***Sensitivity analyses***

Sensitivity analyses were performed for HiSCR, DLQI and safety outcomes, excluding studies that included anti-IL17 treatments that were not commercially available. These analyses maintained the results previously reported. A higher percentage of patients achieved the HiSCR significantly with respect to placebo; OR, 2.00 [1.82-2.20]. Significance was maintained with respect to the PROM DLQI (MD -1.87 [-2.65, -1.09]) and to the safety profile of the variables analyzed; OR, 1.15 [1.03-1.29] (**Supplementary file 6**)

#### ***Publication bias***

Publication bias was assessed using funnel plots, which revealed symmetry consistent with low publication bias regarding efficacy (HiSCR) and safety results (**fig. 6**).

#### ***GRADE***

Data included in the meta-analysis were used to perform the GRADE. The GRADE scale showed high certainty regarding the results of the HiSCR, DLQI and safety outcomes (**Table 4**).

### **DISCUSSION**

HS is a chronic inflammatory skin disease that is difficult to manage, which has led to the use of many different therapeutic tools<sup>1</sup>. Few drugs have been approved with a specific indication for HS, and few randomized clinical trials have been conducted<sup>4</sup>. Since RCTs with anti-IL17 for the management of HS are recent, there are no comparisons on the results of all newer clinical trials with anti-IL17<sup>10-12, 17</sup>. We presented this updated meta-analysis of randomized placebo-controlled clinical trials of anti-IL17 treatment in moderate-to-severe HS.

We show that anti-IL17 biologic drugs are effective treatments with a tolerable safety profile in moderate-to-severe HS, which is supported by a higher percentage of patients achieving HiSCR (even HiSCR75, but not HiSCR90), a reduction in DLQI and an increase in adverse events only at the expense of infections and infestations, particularly candidiasis, with no significant differences with placebo in terms of the number of patients experiencing adverse effects, serious adverse events, headache, development of inflammatory bowel disease or discontinuation of treatment. The analysis of HiSCR across different weeks shows the efficacy profile and the speed of anti-IL17, because this efficacy is significant from week 2, allowing early improvement of this disease.

IL-17 is one of the key proinflammatory cytokines in some inflammatory skin diseases, such as psoriasis and HS<sup>18</sup>. There are 6 members of the IL-17 family, from A to F, with IL-17A, IL-17C and IL-17F being the most associated with autoinflammatory diseases<sup>9,18</sup>.

Secukinumab is an IL-17A neutralizing monoclonal antibody. Its identical clinical trials SUNSHINE and SUNRISE have shown efficacy in moderate-to-severe HS, although in the SUNSHINE trial the group on secukinumab every 4 weeks did not reach the endpoint<sup>11</sup>.

The monoclonal antibody CJM112 has a similar therapeutic target compared to secukinumab<sup>17</sup>. A network meta-analysis<sup>19</sup> positions secukinumab as second-line therapy only after adalimumab, and CJM112 as the 4<sup>th</sup> best option, according to the surface under the cumulative ranking curve (SUCRA).

Bimekizumab is a dual-acting monoclonal antibody that blocks IL-17A and IL-17F. Its clinical trials BE HEARD I and BE HEARD II<sup>12</sup> show its efficacy profile for the management of moderate-to-severe HS. This efficacy had already been observed in a previous clinical trial<sup>10</sup>.

The main clinical trials, SUNSHINE and SUNRISE for secukinumab<sup>11</sup> and BE HEARD I and BE HEARD II for bimekizumab<sup>12</sup> included patients with moderate-to-severe HS as defined by > 5 inflammatory lesions at > 2 anatomical sites for, at least, 1 year in the secukinumab trials and 6 months in the bimekizumab trials. Nonetheless, it was mandatory for bimekizumab trials that patients should have been on prior systemic antibiotic treatment or have a contraindication to it. In these trials, having 20 or more sinus tracts was an exclusion criterion.

In BE HEARD I and BE HEARD II trials<sup>12</sup>, randomization was stratified according to Hurley (II or III, as Hurley I was not included in the trials) and the use or non-use of antibiotics at that time (antibiotic strata vs non-antibiotic strata).

During the SUNSHINE and SUNRISE trials<sup>11</sup>, the use of systemic antibiotics, intralesional corticosteroids or drainage was allowed in case of acute flare-ups, whereas it was prohibited in the bimekizumab trials, which means that the BE HEARD I and BE HEARD II<sup>12</sup> clinical trials better isolated the effect of the drug.

These 4 clinical trials share the primary efficacy endpoint of HiSCR by week 16. HiSCR was calculated based on the number of abscesses (fluctuating and purulent mass with a diameter of > 10 mm), inflammatory nodules, and draining fistulae.

However, other HiSCR-related endpoints of interest, such as HiSCR75, HiSCR90, and HiSCR100, were only reported in BE HEARD I and BE HEARD II<sup>12</sup>, while those of secukinumab were not.

Our meta-analysis shows that twice as many patients on anti-IL17 achieve HiSCR vs placebo, a significant result since week 2, demonstrating its speed. More than twice as many patients achieve HiSCR75 when on bimekizumab vs placebo, with no significant differences achieving a HiSCR90 response, which shows the efficacy profile of these drugs, but how far we still are from the responses observed with biologic drugs in psoriasis<sup>20</sup>. Research into biomarkers to predict the therapeutic response of patients would be of great clinical interest, with the aim of achieving the HiSCR90 response that anti-IL17 has not been shown to achieve in this study.

Regarding DLQI, a drop of 2 points on average is observed with anti-IL17 vs placebo, indicating that it improves the quality of life of patients with HS, although comparison could only be drawn with bimekizumab<sup>12</sup> and CJM112<sup>17</sup>.

More adverse effects were observed when using these biological treatments, mainly due to an increase in infections and infestations, particularly *Candida*; however, it did not lead to a significant increase in treatment withdrawal. Since the Th17 pathway is important as an antifungal immune mechanism<sup>21</sup>, this is an adverse effect already known in psoriatic patients<sup>22</sup>, especially with bimekizumab<sup>23</sup>, also in patients with HS<sup>24</sup>.



The RoB was low, except for the clinical trial with CJM112. The sensitivity analyses of all variables discussed (**Supplementary file 5**) excluded the CJM112 study and maintained the significant differences and their sizes with respect to HiSCR and DLQI. The main change was no significant differences regarding the rate of infections in general and infestations, but it does for candidiasis.

Certainty analysis using the GRADE system was high certainty for HiSCR, DLQI and safety outcomes.

In a meta-analysis of clinical trials on adalimumab in HS<sup>7</sup>, only its weekly administration proved to be effective vs placebo, with a similar clinical response to HiSCR as anti-IL17, but without data on HiSCR75 OR, HiSCR90. The improvement in DLQI, significant for adalimumab only in weekly administration, was lower in that meta-analysis than with anti-IL17 in ours. Regarding the safety profile, they did not report a significant increase in adverse events with adalimumab, including infections vs placebo. However, most outcomes compared in that meta-analysis were the ones reported on week 12<sup>7</sup>.

## LIMITATIONS

Among the limitations, we highlight mainly that only 6 clinical trials have been included. We also found as a limitation the lack of more studies that included variables such as IHS4 or DLQI, either because these variables were not shown in more than 1 study or because they were detailed in a non-comparable manner. Variables HiSCR75 or HiSCR90 only included clinical trials with bimekizumab because they were the only trials that reported it. The safety results were homogenized, being up to week 12 for the Glatt et al.<sup>10</sup> study and up to week 16 in the other<sup>11-12,17</sup>. In addition, we believe that well-designed real-world clinical practice studies should be conducted to obtain long-term safety and efficacy data and the impact on out patients' quality of life.

## CONCLUSIONS

In our systematic review and meta-analysis, treatment with anti-IL17 biologic drugs in patients with HS is effective in achieving an improvement of the disease from week 2, and the quality of life vs placebo. Based on results from a separate analyses, it seems that bimekizumab could be a more effective treatment but with a worse safety profile, with a higher rate of candidiasis, which means that patients on this treatment should be monitored for the risk of candida infections. In addition, we believe that well-designed real-world clinical practice studies should be conducted to obtain long-term safety and efficacy data.

## REFERENCES

1. Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa. *J Am Acad Dermatol*. 2020;82:1045-1058. doi:10.1016/j.jaad.2019.08.090
2. Zouboulis CC, Bechara FG, Fritz K, Goebeler M, Hetzer FH, Just E, et al. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa – Short version. *JDDG J Dtsch Dermatol Ges*. 2024;22:868-889. doi:10.1111/ddg.15412
3. Vazquez BG, Alikhan A, Weaver AL, Wetter DA, Davis MD. Incidence of hidradenitis suppurativa and associated factors: a population-based study of Olmsted County, Minnesota. *J Invest Dermatol*. 2013;133:97-103. doi:10.1038/jid.2012.255
4. González-López MA. Hidradenitis suppurativa. *Med Clínica*. Published online November 2023:S0025775323006036. doi:10.1016/j.medcli.2023.09.018
5. Tchero H, Herlin C, Bekara F, Fluieraru S, Teot L. Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions. *Indian J Dermatol Venereol Leprol*. 2019;85:248-257. doi:10.4103/ijdv.IJDVL\_69\_18
6. Pascual JC, Hernández-Quiles R, Sánchez-García V, Viudez-Martínez A, Belinchón I, Sivera F. Topical and Intralesional Therapies for Hidradenitis Suppurativa: A Systematic Literature Review. *Actas Dermo-Sifiliográficas*. 2024;115:433-448. doi:10.1016/j.ad.2023.12.001
7. Lu JW, Huang YW, Chen TL. Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)*. 2021;100:e26190. doi:10.1097/MD.00000000000026190
8. Malvaso D, Calabrese L, Chiricozzi A, Antonelli F, Coscarella G, Rubegni P, et al. IL-17 Inhibition: A Valid Therapeutic Strategy in the Management of Hidradenitis Suppurativa. *Pharmaceutics*. 2023;15:2450. doi:10.3390/pharmaceutics15102450
9. Kashetsky N, Mufti A, Alabdulrazzaq S, Lytvyn Y, Sachdeva M, Rahat A, et al. Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review. *J Cutan Med Surg*. 2022;26:79-86. doi:10.1177/12034754211035667
10. Glatt S, Jemec GBE, Forman S, Sayed C, Schmieder G, Weisman J, et al. Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. *JAMA Dermatol*. 2021;157:1279-1288. doi: 10.1001/jamadermatol.2021.2905.
11. Kimball AB, Jemec GBE, Alavi A, Reguiat Z, Gottlieb AB, Bechara FG, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. *Lancet*. 2023;401:747-761. doi: 10.1016/S0140-6736(23)00022-3
12. Kimball AB, Jemec GBE, Sayed CJ, Kirby JS, Prens E, Ingram JR, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-

- controlled, multicentre phase 3 trials. *Lancet*. 2024;403:2504-2519. doi: 10.1016/S0140-6736(24)00101-6.
13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi: 10.1136/bmj.n71.
  14. Kimball AB, Sobell JM, Zouboulis CC, Gu Y, Williams DA, Sundaram M, et al. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study. *J Eur Acad Dermatol Venereol*. 2016;30:989-94. doi: 10.1111/jdv.13216
  15. Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. (2019) *Cochrane handbook for systematic reviews of interventions*. John Wiley & Sons 2019.
  16. Guyatt GH, Thorlund K, Oxman AD, Walter SD, Patrick D, Furukawa TA, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. *J Clin Epidemiol*. 2013;66:173-83. doi: 10.1016/j.jclinepi.2012.08.001
  17. Kimball AB, Loesche C, Prens EP, Bechara FG, Weisman J, Rozenberg I, et al. IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study. *Exp Dermatol*. 2022;31:1522-1532. doi:10.1111/exd.14619
  18. Fletcher JM, Moran B, Petrasca A, Smith CM. IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. *Clin Exp Immunol*. 2020;201:121-134. doi:10.1111/cei.13449
  19. Husein-ElAhmed H, Husein-ElAhmed S. Comparative efficacy and therapeutic positioning of biologics in hidradenitis suppurativa: A systematic review with network meta-analysis of randomised trials. *Indian J Dermatol Venereol Leprol*. 2024;1-9. doi: 10.25259/IJDVL\_665\_2023
  20. Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane Database Syst Rev*. 2023;7:CD011535. doi: 10.1002/14651858.CD011535.pub6.
  21. Bacher P, Hohnstein T, Beerbaum E, Röcker M, Blango MG, Kaufmann S, et al. Human Anti-fungal Th17 Immunity and Pathology Rely on Cross-Reactivity against *Candida albicans*. *Cell*. 2019;176:1340-1355.e15. doi: 10.1016/j.cell.2019.01.041.
  22. Feng Y, Zhou B, Wang Z, Xu G, Wang L, Zhang T, et al. Risk of *Candida* Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics:

A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Int J Clin Pract.* 2022;2022:2442603. doi: 10.1155/2022/2442603.

23. Reich K, Warren RB, Lebwohl M, Gooderham M, Strober B, Langley RG, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. *N Engl J Med.* 2021;385:142-152. doi: 10.1056/NEJMoa2102383.
24. Lazaridou I, Vassilopoulos A, Vassilopoulos S, Shehadeh F, Kalligeros M, Mylonakis E, et al. Risk of infection in patients with hidradenitis suppurativa on biologics OR, other immunomodulators: a systematic review and meta-analysis. *Int J Dermatol.* 2024;63:139-149. doi: 10.1111/ijd.16885.

Table 1. Baseline characteristics of the included studies.

Author and Year	Type of study	ClinicalTrials.gov identifier	Study design	Primary endpoint (week)	Severity	Anti-IL17 treatment	n anti-IL17 / Placebo	Age (years), mean±SD anti-IL17 / Placebo	Female, n (%) anti-IL17 / Placebo	Outcomes of Efficacy	Outcomes of Safety	Industrial COI
Glatt et al. 2021	Randomized placebo-controlled clinical trials	NCT03248531	Period 1: 12-week treatment Period 2: 20 week safety follow-up period after the final treatment dose	12	Moderate to severe HS	Bimekizumab 320mg every other week	46 / 21	37.4±11.9 / 40.7±12.8	30 (65) / 14 (67)	HiSCR, HiSCR75, HiSCR90, IHS4, PtGA, DLQI	Incidence, types and severity of AEs during treatment, including clinical laboratory measurements	Yes
Kimball et al. 2022	Randomized placebo-controlled clinical trials	NCT02421172	Period 1: 16 weeks Period 2: 16 weeks followed by a 12-week treatment free follow-up period	16	Moderate to severe HS	JCM112 300mg (the first five doses were administered weekly, followed by injections every other week until week 16)	33 / 33	36±9.8 / 39±10.9	22 (66.7) / 22 (66.7)	HiSCR, HS-PGA responder rate, hsCRP, DLQI	Incidence, types and severity of AEs during treatment	Yes
Kimball et al. 2023	Randomized placebo-controlled clinical trials	NCT03713619 (SUNSHINE)	Period 1: 16 weeks	16	Moderate to severe HS	Secukinumab 300mg every other week; Secukinumab 300mg every 4 weeks	181;180 / 180	37.1±12.5; 35.7±11.7 / 35.5±10.8	102 (56%); 100 (56%) / 102 (57%)	HiSCR, NRS30, DLQI, EQ-5D VAS, AN50	Incidence, types and severity of AEs during treatment, clinical laboratory measurements and immunogenicity	Yes
	Randomized placebo-controlled clinical trials	NCT03713632 (SUNRISE)	Period 2: from week 16 to week 52				180;180 / 183	37.3±11.5; 35.5±11.4 / 36.2±11.3	98 (54%); 103 (57%) / 105 (57%)	HiSCR, NRS30, DLQI, EQ-5D VAS, AN50	Incidence, types and severity of AEs during treatment, clinical laboratory measurements and immunogenicity	
Kimball et al. 2024	Randomized placebo-controlled clinical trials	NCT04242446 (BE HEARD I)	Period 1: 16 weeks	16	Moderate to severe HS	Bimekizumab 320mg every other week; Bimekizumab 320mg every 4 weeks	289;144 / 72	36 (26–46); 35 (27–45) / 33.5 (26–46)*	176 (61%); 98 (68%) / 44 (61%)	HiSCR, HiSCR75, HiSCR90, HiSCR100, DLQI, HSSDD	Incidence, types and severity of AEs during treatment, clinical laboratory measurements	Yes
	Randomized placebo-controlled clinical trials	NCT04242498 (BE HEARD II)	Period 2: from week 16 to week 48				291;144 / 74	35 (27–45); 33 (26–42.5) / 37 (28–47)*	150 (52%); 77 (54%) / 31 (42%)	HiSCR, HiSCR75, HiSCR90, HiSCR100, DLQI, HSSDD	Incidence, types and severity of AEs during treatment, clinical laboratory measurements	Yes

AEs = Adverse events; AN50 = proportion of patients with at least a 50% reduction in the abscess (A) and inflammatory nodule (N) count compared with baseline; COI = Conflict of Interest; DLQI = Dermatology Life Quality Index; EQ-5D VAS = EuroQol-5D visual analogue scale; HiSCR = hidradenitis suppurativa clinical response, defined as a reduction in total abscess and inflammatory nodule count of at least 50% from baseline, with no increase from baseline in abscess and inflammatory nodule or draining tunnel count; HiSCR75 = reduction in total abscess and inflammatory nodule count of at least 75% from baseline with no increase from baseline in abscess or draining tunnel count; HiSCR90 = reduction in total abscess and inflammatory nodule count of at least 90% from baseline with no increase from baseline in abscess or draining tunnel count; HS = hidradenitis Suppurativa; HS-PGA = Hidradenitis Suppurativa Physician's Global Assessment; hsCRP = High-sensitivity C-reactive protein; HSSDD = hidradenitis suppurativa symptom daily diary; IHS4 = International Hidradenitis Suppurativa Severity Score; NRS30 = 30% or more reduction and reduction of two units or more from baseline in Patient's Global Assessment of Skin Pain on a continuous numeric rating scale; PtGA = Patient's Global Assessment

\*In this case, age is expressed as median (interquartile range).

**Table 2.** Results of the meta-analysis regarding the safety profile of the variables analyzed. Forest plots are shown in Supplementary file 5.

Safety outcomes	n studies	n anti-IL17 / placebo	Fixed effect model (OR, 95%CI)	I <sup>2</sup> (%)	P value
Patients with adverse events	10	1661 / 1072	OR, 1.02, 95%CI, 0.86 to 1.20	0	0.84
Serious adverse events	9	1628 / 1039	OR, 1.14, 95%CI, 0.68 to 1.92	0	0.63
Headache	10	1661 / 1072	OR, 1.17, 95%CI, 0.87 to 1.56	0	0.30
Infections and infestations of any organs	10	1661 / 1072	OR, 1.23, 95%CI, 1.03 to 1.46	46	0.02
Candida infections	9	1628 / 1039	OR, 5.61, 95%CI, 2.66 to 11.83	0	< 0.00001
Inflammatory bowel disease	9	1628 / 1039	OR, 2.06, 95%CI, 0.50 to 8.48	0	0.32
Withdrawal of treatment due to adverse effects	10	1661 / 1072	OR, 1.90, 95%CI, 1.00 to 3.59	0	0.05
<b>Total</b>		<b>11528 / 7405</b>	<b>OR, 1.21, 95%CI, 1.09 to 1.34</b>	<b>0%</b>	<b>0.0004</b>

\*CI: Confidence interval; OR: Odds ratio

**Table 3.** Efficacy and safety results of bimekizumab and secukinumab analyzed separately

	Bimekizumab			Secukinumab		
	n studies	OR, CI 95%*	p-value	n studies	OR, CI 95%*	p-value
<b>EFFICACY OUTCOMES</b>						
HiSCR week 2	5	2.62 [1.78 , 3.86]	P < 0.00001	4	1.59 [1.19 , 2.14]	P = 0.002
HiSCR week 4	5	2.39 [1.75 , 3.25]	P < 0.00001	4	2.01 [1.59 , 2.55]	P < 0.00001
HiSCR week 12	5	2.15 [1.63 , 2.84]	P < 0.00001	4	2.09 [1.68 , 2.61]	P < 0.00001
HiSCR week 16	4	2.21 [1.67 , 2.95]	P < 0.00001	4	1.61 [1.30 , 1.99]	P < 0.0001
<b>TOTAL</b>		<b>2.30 [1.98 , 2.69]</b>	<b>P &lt; 0.00001</b>		<b>1.83 [1.63 , 2.06]</b>	<b>P &lt; 0.00001</b>
<b>SAFETY OUTCOMES</b>						
Patients with adverse events	5	1.06 [0.81 , 1.38]	P = 0.69	4	0.99 [0.80 , 1.23]	P = 0.92
Serious adverse events	5	2.39 [0.81 , 7.03]	P = 0.11	4	0.82 [0.44 , 1.54]	P = 0.54
Headache	5	0.85 [0.50 , 1.43]	P = 0.53	4	1.34 [0.94 , 1.92]	P = 0.11
Infections and infestations of any organs	5	1.96 [1.44 , 2.67]	P < 0.0001	4	0.95 [0.76 , 1.19]	P = 0.68
Candida infections	5	11.64 [3.25 , 41.68]	P = 0.0002	4	2.22 [0.84 , 5.87]	P = 0.11
Inflammatory bowel disease	5	1.59 [0.26 , 9.64]	P = 0.62	4	3.07 [0.32 , 29.62]	P = 0.33




<b>Withdrawal of treatment due to adverse effects</b>	5	<b>3.35 [1.09 , 10.27]</b>	<b>P = 0.03</b>	4	1.11 [0.47 , 2.63]	P = 0.81
<b>TOTAL</b>		<b>1.55 [1.30 , 1.85]</b>	<b>P &lt; 0.00001</b>		1.04 [0.91 , 1.19]	P = 0.6

\* A fixed effects model analysis was used since heterogeneity was not significant in any subanalysis.

**Table 4.** Certainty of evidence by GRADE.

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Anti-IL17	Placebo	Relative (95% CI)	Absolute (95% CI)		
Hidradenitis Suppurativa Clinical Response (follow-up: range 2 weeks to 16 weeks)												
10	randomised trials	not serious	not serious	not serious	not serious	none	2480/6608 (37.5%)	991/4257 (23.3%)	OR 1.96 (1.79 to 2.15)	14 more per 100 (from 12 more to 16 more)	⊕⊕⊕⊕ ⊕ High	CRITICAL
Dermatology Life Quality Index (Scale from: 0 to 30)												
5	randomised trials	not serious	not serious	not serious	not serious	none	899	324	-	MD 1.92 fewer (2.68 fewer to 1.16 fewer)	⊕⊕⊕⊕ ⊕ High	CRITICAL
Safety outcomes												
10	randomised trials	not serious	not serious	not serious	not serious	none	1929/11528 (16.7%)	1128/7405 (15.2%)	OR 1.21 (1.09 to 1.34)	3 more per 100 (from 1 more to 4 more)	⊕⊕⊕⊕ ⊕ High	CRITICAL


CI: confidence interval; MD: mean difference; OR: odds ratio



**Figure 1.** Study selection flow diagram (Preferred Reporting Items for Systematic reviews and Meta-Analysis)


	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias): All outcomes	Blinding of outcome assessment (detection bias): All outcomes	Incomplete outcome data (attrition bias): All outcomes	Selective reporting (reporting bias)	Other bias
Glatt et al. 2021 (Bimekizumab)	+	+	+	+	+	+	
Kimball et al. 2022 (CJM112)	?	?	+	-	+	+	
Kimball et al. 2023 (Secukinumab)	+	+	+	+	+	+	
Kimball et al. 2024 (Bimekizumab)	+	+	+	+	+	+	

**Figure 2.** Risk of bias assessment (green = low risk; red = high risk; yellow = unknown).




**Figure 3.** Forest plots showing subgroup analysis in relation to weeks 2, 4, 12, and 16 since first drug administration (total analysis included as well).


a)



b)




**Figure 4.** Forest plot of patientes who achieved HisCR75 (a) and HisCR90 (b)




**Figure 4.** Forest plot showing the mean and standard deviation of changes in DLQI in the studies that reported this variable quantitatively.

A



B)





**Figure 5.** Funnel plots showing low publication bias with respect to HiSCR (a) and safety results (b).

Journal Pre-proof